Review



abt 199  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 97
      Buy from Supplier

    Structured Review

    MedChemExpress abt 199
    Abt 199, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 97/100, based on 255 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/abt+199/Venetoclax/10__1038_slash_s41420___026___03298___2-59-11-9
    Average 97 stars, based on 255 article reviews
    abt 199 - by Bioz Stars, 2026-10
    97/100 stars

    Images

    Related Articles

    Infection:

    Article Title: Multi-omics Profiling Reveals an NF-κB-Driven Anti-apoptotic Network Underlying Resistance to Oncolytic VSV in Prostate Cancer Cells
    Article Snippet: .. Cells were treated with 5 μM of ABT-199, 5 μM of ABT-737, or 10 μM of IKK16 purchased from Med Chem Express, Monmouth Junction NJ, USA; cat#: HY-15531, HY-50907, HY-13687 (respectively) for 24, 48 and 72 h. 6 h prior to each timepoint, LNCaP cells were infected with an MOI of 10, while at 8 h prior to each timepoint, PC3 cells were infected with an MOI of 50. .. Following infection, samples were treated with PrestoBlue, and readout was measured as fluorescence with a SpectraMax iD3 Plate Reader (Molecular Devices).

    Concentration Assay:

    Article Title: Inhibition of V-ATPase function drives apoptosis via GCN1/GCN2 kinase signaling
    Article Snippet: .. Compounds use in this study include: Ǫ-VD-OPH (CAY15260-1, Cayman Chemicals), used at a concentration of 10 μM; GCN2iB (HY-112654, MedChemExpress) used at a concentration of 10 μM; ABT-737 (HY-50907, MedChemExpress) and ABT-199 (HY-15531, MedChemExpress) used at indicated concentrations .. Isogenic KO cell lines in HAP-1, Nalm-6 and HCT-116 (if not published previously) were generated using lentiviral delivery of Cas9 and the sgRNA using the lentiCRISPR V2 backbone (#52961, Addgene) .sgRNA sequences were designed with VBCscore and ordered at Microsynth Austria.

    Article Title: Targeting ST18-mediated pathomechanism in pemphigus vulgaris through voltage-dependent anion channel inhibition
    Article Snippet: .. NHEKs were additionally treated at the same time with ABT-199 [0.5 μmol L –1 ; HY15531S (MedChemExpress, Monmouth Junction, NJ, USA)] for 24 h. Prior to exposure to AK23, Ca 2+ concentration was raised to 1.2 mmol L –1 . ..



    Similar Products

    abt 199  (MedChemExpress)
    97
    MedChemExpress abt 199
    Abt 199, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/abt+199/Venetoclax/10__1038_slash_s41420___026___03298___2-59-11-9
    Average 97 stars, based on 1 article reviews
    abt 199 - by Bioz Stars, 2026-10
    97/100 stars
    		  Buy from Supplier
    abt 199 abt  (MedChemExpress)
    97
    MedChemExpress abt 199 abt
    Abt 199 Abt, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/abt+199/Venetoclax/pm41980559-62-0-12
    Average 97 stars, based on 1 article reviews
    abt 199 abt - by Bioz Stars, 2026-10
    97/100 stars
    		  Buy from Supplier
    abt 199 medchem express cat  (MedChemExpress)
    94
    MedChemExpress abt 199 medchem express cat
    Abt 199 Medchem Express Cat, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/abt+199/Phosal+50+PG/pm41916290-256-49-50
    Average 94 stars, based on 1 article reviews
    abt 199 medchem express cat - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    abt  (MedChemExpress)
    96
    MedChemExpress abt
    (A) GO-term analysis of RNA-seq data from FACS-sorted IgM + immature-like B cells from the comparison of premalignant EµMyc Tet2 −/− (n=5) versus EµMyc (n=6) mice. DEGs (adjusted p-value<0.05 and absolute log 2 (fold change)>1) were subjected to MSigDB Hallmark 2020 in Enrichr. The bar graph depicts the top enriched pathways ranked by p-value, with the number of DEGs contributing to each term indicated in italics at the end of each bar. (B) Volcano plot comparing transcriptional profiles, with a specific focus on apoptotic/BCL2-family gene panel from the RNA-seq analysis described in (A). Significance was defined as adjusted p-value<0.05 and absolute log 2 (fold change)>0.5. Downregulated genes in EµMyc Tet2 −/− subsets are shown in blue; upregulated genes are shown in red; apoptotic/BCL2-family genes, which are not differentially expressed in dark grey, and all other genes in bright grey. (C) Flow cytometric analysis determining the fraction of BCL2 + cells and MFI within the BCL2 + gate in IgM + immature-like B cells (B220 + CD19 + IgM + IgD − ) ( EµMyc : n=6, EµMyc Tet2 −/− : n=4). (D) MFI of BCL-XL and MFI of MCL1 in IgM + immature-like B cells, quantified by flow cytometry ( EµMyc : n=8, EµMyc Tet2 −/− : n=4). (E) Flow cytometric analysis determining the fraction of BIM hi cells and representative histograms for the BIM staining in the IgM + immature-like B cell compartment ( EµMyc : n=8, EµMyc Tet2 −/− : n=4). (F) Flow cytometric assessment determining the fraction of BCL2 + BIM hi cells and representative dot plots of the BCL2 + BIM hi population in IgM + immature-like B cells ( EµMyc : n=3, EµMyc Tet2 −/− : n=4). (G) Cell survival kinetics assessed in vitro for IgM + immature-like B cells (DAPI + B220 + CD19 + IgM + IgD − ) from EµMyc (n=3) and EµMyc Tet2 −/− (n=3) mice, at 0, 2, 6, and 10 hours of culture. Assessment of mitochondrial apoptotic sensitivity via cytochrome c release of IgM + immature-like B cells (ZombieDye − B220 + CD19 + IgM + IgD − cytochromec − ) treated with (H) <t>30</t> <t>µM</t> <t>ABT-199/Venetoclax</t> and (I) 1 µM S63845. For both treatments, cytochrome c release in DMSO controls and treated samples is shown as a line plot (left) and as a bar graph (right), depicting the fold change relative to DMSO ( EµMyc : n=3, EµMyc Tet2 −/− : n=4). Bar plots show median with interquartile range. Statistical significance was assessed using unpaired t-test (A-F, H, I), or two-way ANOVA (G) with Holm-Šidák correction for multiple comparisons. Normality was evaluated using the Shapiro-Wilk test. MFI = mean fluorescence intensity, ns = not significant, *p<0.05, **p<0.005.
    Abt, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/abt+199/Venetoclax/bio_rxiv__64898__2026__03__20__712678-214-3-4
    Average 96 stars, based on 1 article reviews
    abt - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier

    Image Search Results


    (A) GO-term analysis of RNA-seq data from FACS-sorted IgM + immature-like B cells from the comparison of premalignant EµMyc Tet2 −/− (n=5) versus EµMyc (n=6) mice. DEGs (adjusted p-value<0.05 and absolute log 2 (fold change)>1) were subjected to MSigDB Hallmark 2020 in Enrichr. The bar graph depicts the top enriched pathways ranked by p-value, with the number of DEGs contributing to each term indicated in italics at the end of each bar. (B) Volcano plot comparing transcriptional profiles, with a specific focus on apoptotic/BCL2-family gene panel from the RNA-seq analysis described in (A). Significance was defined as adjusted p-value<0.05 and absolute log 2 (fold change)>0.5. Downregulated genes in EµMyc Tet2 −/− subsets are shown in blue; upregulated genes are shown in red; apoptotic/BCL2-family genes, which are not differentially expressed in dark grey, and all other genes in bright grey. (C) Flow cytometric analysis determining the fraction of BCL2 + cells and MFI within the BCL2 + gate in IgM + immature-like B cells (B220 + CD19 + IgM + IgD − ) ( EµMyc : n=6, EµMyc Tet2 −/− : n=4). (D) MFI of BCL-XL and MFI of MCL1 in IgM + immature-like B cells, quantified by flow cytometry ( EµMyc : n=8, EµMyc Tet2 −/− : n=4). (E) Flow cytometric analysis determining the fraction of BIM hi cells and representative histograms for the BIM staining in the IgM + immature-like B cell compartment ( EµMyc : n=8, EµMyc Tet2 −/− : n=4). (F) Flow cytometric assessment determining the fraction of BCL2 + BIM hi cells and representative dot plots of the BCL2 + BIM hi population in IgM + immature-like B cells ( EµMyc : n=3, EµMyc Tet2 −/− : n=4). (G) Cell survival kinetics assessed in vitro for IgM + immature-like B cells (DAPI + B220 + CD19 + IgM + IgD − ) from EµMyc (n=3) and EµMyc Tet2 −/− (n=3) mice, at 0, 2, 6, and 10 hours of culture. Assessment of mitochondrial apoptotic sensitivity via cytochrome c release of IgM + immature-like B cells (ZombieDye − B220 + CD19 + IgM + IgD − cytochromec − ) treated with (H) 30 µM ABT-199/Venetoclax and (I) 1 µM S63845. For both treatments, cytochrome c release in DMSO controls and treated samples is shown as a line plot (left) and as a bar graph (right), depicting the fold change relative to DMSO ( EµMyc : n=3, EµMyc Tet2 −/− : n=4). Bar plots show median with interquartile range. Statistical significance was assessed using unpaired t-test (A-F, H, I), or two-way ANOVA (G) with Holm-Šidák correction for multiple comparisons. Normality was evaluated using the Shapiro-Wilk test. MFI = mean fluorescence intensity, ns = not significant, *p<0.05, **p<0.005.

    Journal: bioRxiv

    Article Title: TET2 loss promotes premalignant survival and clonal selection in MYC-driven B cell lymphoma

    doi: 10.64898/2026.03.20.712678

    Figure Lengend Snippet: (A) GO-term analysis of RNA-seq data from FACS-sorted IgM + immature-like B cells from the comparison of premalignant EµMyc Tet2 −/− (n=5) versus EµMyc (n=6) mice. DEGs (adjusted p-value<0.05 and absolute log 2 (fold change)>1) were subjected to MSigDB Hallmark 2020 in Enrichr. The bar graph depicts the top enriched pathways ranked by p-value, with the number of DEGs contributing to each term indicated in italics at the end of each bar. (B) Volcano plot comparing transcriptional profiles, with a specific focus on apoptotic/BCL2-family gene panel from the RNA-seq analysis described in (A). Significance was defined as adjusted p-value<0.05 and absolute log 2 (fold change)>0.5. Downregulated genes in EµMyc Tet2 −/− subsets are shown in blue; upregulated genes are shown in red; apoptotic/BCL2-family genes, which are not differentially expressed in dark grey, and all other genes in bright grey. (C) Flow cytometric analysis determining the fraction of BCL2 + cells and MFI within the BCL2 + gate in IgM + immature-like B cells (B220 + CD19 + IgM + IgD − ) ( EµMyc : n=6, EµMyc Tet2 −/− : n=4). (D) MFI of BCL-XL and MFI of MCL1 in IgM + immature-like B cells, quantified by flow cytometry ( EµMyc : n=8, EµMyc Tet2 −/− : n=4). (E) Flow cytometric analysis determining the fraction of BIM hi cells and representative histograms for the BIM staining in the IgM + immature-like B cell compartment ( EµMyc : n=8, EµMyc Tet2 −/− : n=4). (F) Flow cytometric assessment determining the fraction of BCL2 + BIM hi cells and representative dot plots of the BCL2 + BIM hi population in IgM + immature-like B cells ( EµMyc : n=3, EµMyc Tet2 −/− : n=4). (G) Cell survival kinetics assessed in vitro for IgM + immature-like B cells (DAPI + B220 + CD19 + IgM + IgD − ) from EµMyc (n=3) and EµMyc Tet2 −/− (n=3) mice, at 0, 2, 6, and 10 hours of culture. Assessment of mitochondrial apoptotic sensitivity via cytochrome c release of IgM + immature-like B cells (ZombieDye − B220 + CD19 + IgM + IgD − cytochromec − ) treated with (H) 30 µM ABT-199/Venetoclax and (I) 1 µM S63845. For both treatments, cytochrome c release in DMSO controls and treated samples is shown as a line plot (left) and as a bar graph (right), depicting the fold change relative to DMSO ( EµMyc : n=3, EµMyc Tet2 −/− : n=4). Bar plots show median with interquartile range. Statistical significance was assessed using unpaired t-test (A-F, H, I), or two-way ANOVA (G) with Holm-Šidák correction for multiple comparisons. Normality was evaluated using the Shapiro-Wilk test. MFI = mean fluorescence intensity, ns = not significant, *p<0.05, **p<0.005.

    Article Snippet: Briefly, 30 μM ABT-199/Venetoclax, (MedChemExpress, HY-15531) 1 μM S63845 (MedChemExpress, HY-100741), 20 μM Alamethicin (MedChemExpress, HY-N6708) and 1% dimethyl sulfoxide (DMSO; Merck, D5879) were diluted to 2X the desired final concentration in 25 μl of 0.002% digitonin (Merck, D141) prepared in MEB buffer (Mannitol Experimental Buffer: 10 mM HEPES (Merck, H0887) pH 7.5, 150 mM mannitol (Merck, M9647), 150 mM KCl, 1 mM EGTA (Merck, E3889), 1 mM EDTA (Merck, ED4S), 0.1% BSA (Sigma-Aldrich, 12659), 5 mM succinate (Merck, S3674)).

    Techniques: RNA Sequencing, Comparison, Flow Cytometry, Staining, In Vitro, Fluorescence